SCPH Revenue Up 99%
(NASDAQ:SCPH), a commercial-stage pharmaceutical company focused on subcutaneous drug delivery for heart failure and chronic kidney disease patients, delivered its second quarter 2025 earnings results on August 7, 2025. The most notable headline: Revenue (GAAP) climbed to $16.0 million in Q2 2025, beating analyst expectations of $15.41 million (GAAP). This performance marked a 99% increase over the prior-year period (GAAP), driven mainly by strong adoption of its lead product, FUROSCIX, and rapid expansion into the chronic kidney disease market. Despite robust top-line growth and outperformance on revenue, profitability remains a challenge for the company, with losses continuing due to high operating and R costs. The quarter reflected strong commercial momentum, but ongoing investment and cash usage require attention in the months ahead.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
scPharmaceuticals is centered on developing and commercializing subcutaneous therapies, with its primary focus on FUROSCIX, a patented formulation of furosemide. FUROSCIX allows patients with heart failure or kidney disease to receive high-strength diuretic therapy at home instead of in the hospital. This product targets both cost reduction for healthcare systems and greater convenience for patients, seeking to shift treatment outside facility settings.
Source Fool.com
scPharmaceuticals Stock
scPharmaceuticals is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 16 € there is potential for a 307.33% increase which would mean more than doubling the current price of 3.93 € for scPharmaceuticals.
